Farmácia/Notícias da Indústria
Estudo de coorte retrospectiva | Incidência de eventos cardíacos adversos maiores com imunoterápicos.
19 Jun, 2022 | 13:00hConteúdos relacionados:
Cardiotoxicity of immune checkpoint inhibitors – ESMO Open
Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature
Comparação de estratégias para conservação do meio de contraste iodado intravascular para tomografia computadorizada durante um período de escassez.
16 Jun, 2022 | 13:43hComparison of Strategies to Conserve Iodinated Intravascular Contrast Media for Computed Tomography During a Shortage – JAMA (gratuito por tempo limitado)
Comunicado de imprensa: Amid Global Shortage, Study Shows How to Cut Contrast Dye Use 83% – University of California, San Francisco (UCSF)
Comentário no Twitter
This modeling study estimated that intravenous contrast use for CT scans could be reduced by approximately 80% by using a combination of dose-reduction strategies. https://t.co/hlnvkdEECS
— JAMA (@JAMA_current) June 9, 2022
[Comunicado de imprensa – ainda não publicado] Médicos alertam que as mulheres não estão sendo informadas de que um anestésico comum pode reduzir a efetividade dos anticoncepcionais.
16 Jun, 2022 | 13:08hComentário: Women in UK ‘seldom’ told drug used in surgery can impede contraception – The Guardian
Revisão | Retirada de medicamentos no cuidado paliativo oncológico.
16 Jun, 2022 | 13:07hDeprescribing in Palliative Cancer Care – Life
Diretriz sobre tratamento antimicrobiano inicial da sepse.
14 Jun, 2022 | 14:04hStatement on initial antimicrobial treatment of sepsis – Faculty of Intensive Care Medicine
Comentário no Twitter
🚨Statement on initial antimicrobial treatment of sepsis🚨
Full statement and documents available➡️ https://t.co/jWexX1VDDd @AoMRC pic.twitter.com/kQdJrZ2hOA
— FICMNews (@FICMNews) June 4, 2022
Por que a forma de administração pode ser a chave para novos medicamentos.
14 Jun, 2022 | 13:42hWhy drug delivery is the key to new medicines – Nature Medicine
Combinação de infusões de anticorpos anti-HIV suprimem o vírus por período prolongado.
14 Jun, 2022 | 13:21hComunicado de imprensa: Combination anti-HIV antibody infusions suppress virus for prolonged period – National Institutes of Health
Estudo original: Combination anti-HIV antibodies provide sustained virological suppression – Nature
Comentários no Twitter
Still don't get the enthusiasm for HIV Rx with bNAbs.
Compared to existing antivirals, they have:
– more baseline resistance
– the need to scale up new resistance tests
– more resource requirements (IV administration)
– … and, if like other monoclonals, $$$
What am I missing? https://t.co/7WZmIjutwE— Paul Sax (@PaulSaxMD) June 1, 2022
This is a wonderful advance.
"Our data demonstrate that combination therapy with broadly neutralizing monoclonal antibodies can provide long-term virological suppression without antiretroviral therapy in individuals with HIV"https://t.co/DKNVSlg3mC
— Michael Worobey (@MichaelWorobey) June 2, 2022
#ADA2022 – Estudo randomizado | Dulaglutida semanal para tratamento de jovens com diabetes tipo 2.
13 Jun, 2022 | 15:00hOnce-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comunicado de imprensa: Once Weekly Drug Helps Control Pediatric Type 2 Diabetes – American Diabetes Association
Comentário no Twitter
Trial compared once-weekly dulaglutide with placebo for glycemic control in youths with type 2 diabetes who may have been receiving metformin or basal insulin. Dulaglutide was superior at 26 weeks. #ADA2022 https://t.co/P6PubXvHOR pic.twitter.com/1JPIT5IyTe
— NEJM (@NEJM) June 4, 2022
Vacinação materna: revisão das evidências e recomendações atuais.
13 Jun, 2022 | 14:12h
Comentário no Twitter
AJOG Expert Review: Maternal vaccination: a review of current evidence and recommendations – Placental transfer of IgG antibodies from maternal to fetal circulation https://t.co/yd3DQpwSoD pic.twitter.com/obicClLhzC
— AJOG (@AJOG_thegray) April 1, 2022
Estudo de coorte nacional | Associação entre terapia de supressão androgênica e doença cardiovascular e mortalidade por todas as causas no câncer de próstata não metastático.
13 Jun, 2022 | 13:57hComentário: ADT for Prostate Cancer: What’s the Risk on the Heart? – Medscape (necessário cadastro gratuito)